Clinical Trials Sponsored by ISPO Cancer Prevention and Research Institute

Total 2403 results

H. Lee Moffitt Cancer Center and Research Institute
Patient-Centered Outcomes Research Institute

Completed

Navigator Guided e-Psychoeducational Intervention

Prostate Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
GlaxoSmithKline

Recruiting

Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

Penile Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
BeiGene

Recruiting

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

Prostate Cancer | Stage IV Prostate Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Active, not recruiting

Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination Immunotherapy

Renal Cell Carcinoma Stage IV

United States
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca

Terminated

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

Breast Cancer | Hormone Receptor Positive Tumor

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Completed

TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer

Breast Cancer | Breast Cancer - Female | Breast Cancer - Male

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Completed

Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention

Graft Versus Host Disease | GVHD

United States
H. Lee Moffitt Cancer Center and Research Institute
Bayer

Completed

Assess Gamma H2AX Positivity in Circulating Prostate Cancer Cells Before and After Radium 223

Prostate Cancer | Prostate Adenocarcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Celgene

Completed

Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Completed

Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD)

Graft-Versus-Host Disease

United States
H. Lee Moffitt Cancer Center and Research Institute
Celgene

Completed

Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide

Myeloma

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Terminated

Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)

Liver Cancer

United States
Beijing Cancer Prevention & Treatment Society
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Recruiting

A Prospective, Multicenter, Non-interventional, Real-world Study to Characterize Changes in Molecular Markers After Three Weeks of Targeted Therapy With Oxitinib in EGFRm NSCLC (pre-FLAME)

Non Small Cell Lung Cancer

China
Beijing Cancer Prevention & Treatment Society
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Recruiting

Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib (FLAME)

Non Small Cell Lung Cancer

China
University of Texas Southwestern Medical Center
Cancer Prevention Research Institute of Texas; Arcus Biosciences, Inc.

Recruiting

Domvanalimab and Zimberelimab in Advanced Liver Cancers

Hepatocellular Carcinoma | Cholangiocarcinoma | Liver Cancer | Hepatobiliary Cancer

United States
Centers for Disease Control and Prevention
Children's National Research Institute; Jacobi Medical Center; Howard University

Completed

Pediatric Impact: Promoting Adherence to Medications Among HIV-infected Children

HIV Infections

United States
Vanderbilt University
Vanderbilt University Medical Center; Centers for Disease Control and Prevention and other collaborators

Completed

Pilot Study to Assess Flares Following Inactivated Influenza Vaccine in Children With Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus (SLE)

United States
H. Lee Moffitt Cancer Center and Research Institute
Pediatric Cancer Foundation

Completed

Metformin in Children With Relapsed or Refractory Solid Tumors

Solid Tumors | Primary Brain Tumors

United States
H. Lee Moffitt Cancer Center and Research Institute
Reliable Cancer Therapies

Terminated

Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain

Pain | Lymphoma | Cancer | Neoplasm Metastasis | Multiple Myeloma | Hematologic Malignancy | Tumor | Unresectable Malignant Neoplasm | Malignant Solid Tumor

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Recruiting

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

Melanoma Stage IV | BRAF V600 Mutation | Melanoma Stage III

United States
H. Lee Moffitt Cancer Center and Research Institute
Amgen

Active, not recruiting

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Breast Cancer | Invasive Breast Carcinoma | Invasive Ductal Breast Carcinoma | Ductal Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Exelixis

Completed

Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca

Terminated

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

Bladder Cancer | Carcinoma in Situ of Bladder

United States
H. Lee Moffitt Cancer Center and Research Institute
Celgene

Completed

Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
H. Lee Moffitt Cancer Center and Research Institute
Bayer

Completed

Single Agent Regorafenib in Refractory Advanced Biliary Cancers

Cancer of the Bile Duct

United States
H. Lee Moffitt Cancer Center and Research Institute
Bayer

Completed

Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma

Cholangiocarcinoma | Gastrointestinal Tumor | Gall Bladder Carcinoma | Biliary Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Completed

Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)

Chronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS)

United States
H. Lee Moffitt Cancer Center and Research Institute
Sanofi

Terminated

Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery

Pancreatic Neoplasms

United States
H. Lee Moffitt Cancer Center and Research Institute
GlaxoSmithKline

Completed

A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia

Cancer Cachexia

United States
H. Lee Moffitt Cancer Center and Research Institute
Sanofi

Terminated

Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem

Lung Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Bayer

Completed

Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer

Rectal Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Completed

Yoga for Aromatase Inhibitor-associated Joint Pain

Breast Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Completed

Facts and Attitudes About Clinical Trials (FACT)

Cancer | Neoplasm

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Terminated

P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome

Neuroendocrine Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Sanofi

Completed

Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC

Non-Small Cell Lung Cancer

United States, Germany, Puerto Rico
H. Lee Moffitt Cancer Center and Research Institute
GlaxoSmithKline

Completed

A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Carcinoma

Rectal Neoplasms

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Terminated

Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas

Sarcoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Completed

Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement

Tobacco Dependence

United States
H. Lee Moffitt Cancer Center and Research Institute
Bayer

Completed

Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma

Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Bayer

Terminated

Depocyt® With Sorafenib in Neoplastic Meningitis

Neoplastic Meningitis

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Completed

A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma

Glioblastoma | Anaplastic Astrocytoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Completed

Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization

Neuroendocrine Tumor | Islet Cell Tumor

United States
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca

Completed

Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas

Gastric Cancer | Esophageal Cancer

United States, Puerto Rico
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Terminated

A Phase I/II Study of Sunitinib and Dacarbazine

Melanoma

United States
Baylor College of Medicine
National Cancer Institute (NCI); Cancer Prevention Research Institute of Texas and other collaborators

Active, not recruiting

TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer (TACTIC)

Breast Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); Upjohn

Completed

Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11)

Lymphoma | Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
Dendreon

Recruiting

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Servier

Recruiting

CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
ImmunoRestoration

Recruiting

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

HER2-positive Breast Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Recruiting

Axitinib + Ipilimumab in Advanced Melanoma

Melanoma

United States

Clinical Trials Sponsored by ISPO Cancer Prevention and Research Institute

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations